Two cases of therapy-refractory chilblain lupus erythematosus successfully treated with deucravacitinib.

LupusJul 28, 2026 (epub)
Case ReportDermatology

Robin Springer, Andrew Moufarrej, Bernhard Homey et al.

✦ AI-curated · Sources linked

Case in brief

Two patients with long-lasting, therapy-refractory chilblain lupus erythematosus were treated with deucravacitinib, a selective TYK2-inhibitor. Both patients exhibited rapid improvement in their skin lesions and associated symptoms. The treatment was well tolerated, with one patient reporting intermittent acne lesions as a side effect.

Diagnostic / clinical pearl

Deucravacitinib may be an effective off-label treatment option for patients with refractory chilblain lupus erythematosus.

Why it matters

Chilblain lupus erythematosus poses significant treatment challenges, and identifying effective therapies is crucial for improving patient outcomes.

Source

PubMed · PMID 42517243

Published in Lupus. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.